Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 15/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402837 | 0.98 | KMO (0.53) | SLC9A1KMOCYP2C9CYP2C19ADRA1D | |
| SCHEMBL31188362 | 0.94 | SLC9A1 (0.50) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL932371 | 0.86 | SLC9A1 (0.50) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL400977 | 0.85 | SLC9A1 (0.56) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL27195840 | 0.84 | SLC9A1 (0.55) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL1918275 | 0.82 | RBP4 (0.58) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL1809088 | 0.81 | RBP4 (0.57) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL664135 | 0.81 | SSTR5 (0.46) | CYP2C19CYP2D6RBP4 | |
| SCHEMBL3912829 | 0.80 | RBP4 (0.58) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A | |
| SCHEMBL17134229 | 0.79 | SLC9A1 (0.55) | SLC9A1CYP2C9CYP2C19ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4148045-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B] INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4116294-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-3378854-B1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220259627-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | SLC9A1 4024/4885KMO 599/4885CYP2C9 3139/4885 |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | AZI2, GABBR2, CNDP2 | SLC9A1 636/4885KMO 967/4885CYP2C9 458/4885 |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | AZI2, GABBR2, CNDP2 | SLC9A1 636/4885KMO 967/4885CYP2C9 458/4885 |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | SLC9A1 1588/4885KMO 1198/4885CYP2C9 1367/4885 |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | SLC9A1 1863/4885KMO 440/4885CYP2C9 3394/4885 |
| US-20220259627-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | SLC9A1 1885/4885KMO 371/4885CYP2C9 3306/4885 |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | SLC9A1 869/4885KMO 401/4885CYP2C9 2003/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | SLC9A1 4024/4885KMO 599/4885CYP2C9 3139/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | SLC9A1 869/4885KMO 401/4885CYP2C9 2003/4885 |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | SLC9A1 1863/4885KMO 440/4885CYP2C9 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.